Host: Shira Johnson, MD 

Guest: Anne Peters, MD 

Guest: Donna Miller, MSN, FNP-C, CDE 

Guest: Jana Conley 


 This activity explores new and emerging treatments for type 1 diabetes, including a dual sodium glucose transporter 1/2 inhibitor, and provides both clinician and patient perspectives on their use.

Host: Shira Johnson, MD Guest: Anne Peters, MD Guest: Donna Miller, MSN, FNP-C, CDE Guest: Jana Conley This activity explores new and emerging treatments for type 1 diabetes, including a dual sodium glucose transporter 1/2 inhibitor, and provides both clinician and patient perspectives on their use.

When Insulin Isn’t Enough: Exploring Dual SGLT1 and SGLT2 Inhibition in T1DM

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease.
Because when it comes to diabetes, glucose control is just the beginning.

Medicine

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease. Because when it comes to diabetes, glucose control is just the beginning.

Share When Insulin Isn’t Enough: Exploring Dual SGLT1 and SGLT2 Inhibition in T1DM

Sign up to save your podcasts

When Insulin Isn’t Enough: Exploring Dual SGLT1 and SGLT2 Inhibition in T1DM

When Insulin Isn’t Enough: Exploring Dual SGLT1 and SGLT2 Inhibition in T1DM